128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified

Therapeutic assets addressing Peripheral T-Cell Lymphoma, Not Otherwise Specified, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
PF-08046044 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
pf-08046045 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
Pomalidomide Peripheral T-Cell Lymphoma, Not Otherwise Specified	Sun Yat-sen University	P1/2	CC (43)
q702 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Mayo Clinic	P1	CC (43)
Ruxolitinib Phosphate Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	P1	CC (43)
Sgn-35 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (43)
Teclistamab Peripheral T-Cell Lymphoma, Not Otherwise Specified	CellCentric Ltd.	P1/2	CC (43)
Tolinapant Peripheral T-Cell Lymphoma, Not Otherwise Specified	Taiho Oncology, Inc.	P1	CC (43)
Venetoclax Peripheral T-Cell Lymphoma, Not Otherwise Specified	Children's Hospital Medical Center, Cincinnati	P1/2	CC (43)
Anti-Cd7 Car-T Cells Peripheral T-Cell Lymphoma, Not Otherwise Specified	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	P1	CC (42)
Anti Cd30 Car-T Cell Peripheral T-Cell Lymphoma, Not Otherwise Specified	Zhejiang University	Early P1	C (39)
Autologous Ccr4 Car T Cells Peripheral T-Cell Lymphoma, Not Otherwise Specified	National Cancer Institute (NCI)	P1	C (39)
Bitr2101 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Boston Immune Technologies and Therapeutics	P1	C (39)
c7r.cd30.car-ebvst cells Peripheral T-Cell Lymphoma, Not Otherwise Specified	Baylor College of Medicine	P1	C (39)
cd30.car-t Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tessa Therapeutics	P1	C (39)
cht101 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Tianjin Medical University Cancer Institute and Hospital	P1	C (39)
Ebv Tcr-T Peripheral T-Cell Lymphoma, Not Otherwise Specified	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Early P1	C (39)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Peripheral T-Cell Lymphoma, Not Otherwise Specified	Mayo Clinic	P1	C (39)
pf-08046032 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Pfizer	P1	C (39)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta Peripheral T-Cell Lymphoma, Not Otherwise Specified	Mayo Clinic	P1	C (39)
Wu-Cart-007 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Washington University School of Medicine	P1	C (39)
Calaspargase Pegol Peripheral T-Cell Lymphoma, Not Otherwise Specified	New York Medical College	Early P1	C (36)
Pralatraxate Peripheral T-Cell Lymphoma, Not Otherwise Specified	New York Medical College	Early P1	C (36)
Chi-Gvm Peripheral T-Cell Lymphoma, Not Otherwise Specified	The First Affiliated Hospital with Nanjing Medical University	N/A	D (30)
Sasanlimab Peripheral T-Cell Lymphoma, Not Otherwise Specified	Pfizer	P1	D (28)
Anti-Trbc1 Car-T Cells Peripheral T-Cell Lymphoma, Not Otherwise Specified	Second Affiliated Hospital, School of Medicine, Zhejiang University	P1	NR ()
Chidamide Analog Peripheral T-Cell Lymphoma, Not Otherwise Specified	Jiangsu HengRui Medicine Co., Ltd.	P3	NR ()
Ro-Choep-21 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Fondazione Italiana Linfomi - ETS	P1/2	NR ()

Showing 101 to 128 of 128 assets

PreviousPage 3 of 3Next